Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Virtual CME : JIA Update 2023 - Juvenile Idiopathic Arthritis
The 2023 Virtual Continuing Medical Education (CME) session on Juvenile Idiopathic Arthritis (JIA) provided crucial updates on the latest advancements in the diagnosis and management of this complex pediatric condition. Key topics included the introduction of novel biologic therapies, improved diagnostic criteria, and personalized treatment approaches. Experts highlighted the significance of early and accurate diagnosis, emphasizing the use of advanced imaging techniques and updated clinical guidelines to distinguish JIA subtypes, which is essential for tailoring effective treatment plans.
A major focus of the CME was on the evolving landscape of biologic treatments and their role in achieving disease remission. Presenters discussed the latest data on biologics such as Adalimumab, Tocilizumab, and newer agents targeting specific immune pathways. They also underscored the importance of monitoring for side effects and long-term safety, given the chronic nature of JIA. Additionally, the session addressed the critical role of multidisciplinary care, involving rheumatologists, physical therapists, and pediatricians, to optimize patient outcomes. The virtual format allowed for interactive discussions and case studies, providing participants with practical insights and strategies to enhance their clinical practice in managing JIA.
Therefore, get an overall knowledge of virtual CME : JIA update 2023 - juvenile idiopathi
See More Webinars @ Hidoc Webinars
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation